Healthcare
Stoke Therapeutics, Inc.(STOK)
Live Price
Offline$28.68
-5.87% today
1Y Change
+166.70%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $1.96B
- Revenue Growth
- +404.5%
- EPS Growth
- +92.7%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stoke Therapeutics, Inc. (STOK) is a Healthcare stock with a market cap of $1.96B and listed on NASDAQ. The stock last traded around $28.68 and up 166.7% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of +404.5%, EPS growth of +92.7%, a dividend yield of 0.0%. What stands out right now is revenue +404.5%, EPS +92.7%, free cash flow +151.6% with operating margin -11.2% and ROIC -5.7%. Valuation already assumes a fairly strong business story at price/sales 10.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STOK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+404.5% vs +7.6% peer median
Operating Margin
Below sector median
-11.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +404.5% and EPS at +92.7%, with operating margin around -11.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.4% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -2.4% | -7.8% | โ |
2026 Mar 16, 2026 | -29.3% | -3.2% | -1.6% | +5.6% |
2025 Nov 4, 2025 | -20.4% | -9.9% | -0.9% | +22.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STOK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STOK Max Drawdown
-37.16%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STOK and SPY.
Company Overview
Stoke Therapeutics, Inc.
NASDAQ Global Select
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
- Leadership
- Ian F. Smith
- IPO Date
- Jun 19, 2019
- Employees
- 128
- Street Address
- 45 Wiggins Avenue
- Mailing
- Bedford, MA, 01730
- Region
- Bedford, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 430 8200
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 10.6
- Price/Book
- 5.5
Growth
- Revenue
- +404.5%
- EPS
- +92.7%
- Free Cash Flow
- +151.6%
Profitability
- Gross Margin
- 98.9%
- Operating Margin
- -11.2%
- Net Margin
- -3.7%
- ROE
- -2.0%
- ROIC
- -5.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 5.28
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.